Phathom Pharmaceuticals Files 8-K
Ticker: PHAT · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1783183
| Field | Detail |
|---|---|
| Company | Phathom Pharmaceuticals, Inc. (PHAT) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Phathom Pharma filed an 8-K today, details TBD.
AI Summary
On December 11, 2024, Phathom Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding transactions, financial figures, or significant corporate actions were provided in the excerpt.
Why It Matters
This filing signals a corporate event or update from Phathom Pharmaceuticals, Inc. that requires public disclosure under SEC regulations.
Risk Assessment
Risk Level: low — The filing is a standard disclosure form without immediate negative or positive financial implications presented.
Key Players & Entities
- Phathom Pharmaceuticals, Inc. (company) — Registrant
- December 11, 2024 (date) — Date of report
FAQ
What specific event triggered this 8-K filing for Phathom Pharmaceuticals, Inc.?
The provided excerpt does not specify the exact event, only that it falls under 'Other Events'.
When was this 8-K report filed?
The report was filed on December 11, 2024.
What is the principal executive office address for Phathom Pharmaceuticals, Inc.?
The principal executive offices are located at 100 Campus Drive, Suite 102, Florham Park, New Jersey 07932.
What is the telephone number for Phathom Pharmaceuticals, Inc.?
The registrant's telephone number is (877) 742-8466.
What is the Standard Industrial Classification (SIC) code for Phathom Pharmaceuticals, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,189 words · 5 min read · ~4 pages · Grade level 15.3 · Accepted 2024-12-11 08:05:33
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share PHAT The Nasdaq Global Se
Filing Documents
- d904037d8k.htm (8-K) — 29KB
- 0001193125-24-274876.txt ( ) — 154KB
- phat-20241211.xsd (EX-101.SCH) — 3KB
- phat-20241211_lab.xml (EX-101.LAB) — 18KB
- phat-20241211_pre.xml (EX-101.PRE) — 11KB
- d904037d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements This report contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about: the ultimate decision by the FDA on the action requested in the CP and the timing any FDA action regarding the CP; the possible extension of NCE exclusivity to VOQUEZNA tablets; and the expected duration of patent term extension for VOQUEZNA. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in Phathom's business, including, without limitation: the FDA may reject Phathom's request to correct the Orange Book listings identifying the expiration date for the NCE exclusivity period on the VOQUEZNA tablets Orange Book listings; the FDA may take longer than the Company expects to act on its CP, if at all; members of the public may comment on the Company's CP which may influence the FDA's decision; Phathom's ability to obtain and maintain intellectual property protection, including patent term extensions, and non-patent regulatory exclusivity for vonoprazan; Phathom may face competition earlier than expected if it loses or fails to obtain any of its patent protection or non-patent regulatory exclusivity for VOQUEZNA tablets; and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by t
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHATHOM PHARMACEUTICALS, INC. Date: December 11, 2024 By: /s/ Molly Henderson Molly Henderson Chief Financial and Business Officer